reports
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congres...
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case exceeding objective response rate (ORR) benchmarks in these difficult to treat populations In the monotherapy expansion cohorts, irrespective of tumor type, patients treated with MDNA11, as the next treatment following progression on immune checkpoi...
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Upda...
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as autoimmune and inflammatory diseases is pleased to announce that it will host a live webinar on December 10, 2025 at 08:30 AM Eastern Time. As previously announced, Medicenna will present updated clinical data from the ABILITY-1 Phase 1/2...
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Re...
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10th December, 2025 Fondazion Melanoma Onus will sponsor a new clinical trial (NEO-CYT) at up to 12 cancer centres in Italy to evaluate if MDNA11 in combination with leading check-point inhibitors, prior to surgery (neoadjuvant), can improve outcomes in patients with earlier stage high-risk melanoma MDNA113, Medicenna’s first-in...
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 ...
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale”, a leading cancer centre in Europe The NEO-CYT Study will evaluate MDNA11 as a neoadjuvant immunotherapy in earlier-stage melanoma patients whose im...
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented ...
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025 TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that updated MDNA11 clinical data will be presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025 taking place December 10-12, ...
Medicenna Therapeutics Announces Participation in Upcoming Conferences
Medicenna Therapeutics Announces Participation in Upcoming Conferences TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as autoimmune and inflammatory diseases is pleased to announce its participation in several upcoming conferences. These events provide an opportunity for Medicenna to showcase its innovative therapies and engage with the industry and investment community. Upcoming ...
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcar...
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference TORONTO and HOUSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as autoimmune and inflammatory diseases, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in the ROTH 4th Annual Healthcare Opportunities Conference, taking place at the Metropolitan Club in New York...
Medicenna Announces Results of Annual Meeting of Shareholders
Medicenna Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the voting results from the Company’s annual meeting of shareholders held today, September 25, 2025 (the “Meeting”). Medicenna is pleased to announce that all nominees listed in the management information circular dated August 13, 2025 (the “Circular”), were elected as directors. The results...
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Inv...
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference TORONTO and HOUSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage cancer immunotherapy company focused on the development of Superkines, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025, at the Lotte New York Palace Hotel in New York Cit...
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Res...
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL-2 superkine by exceeding ORR benchmarks demonstrated with other competing therapies in similar checkpoint resistant tumor types A patient with pancreatic cancer and a melanoma cancer patient remain cancer free for 18 and 6 months, respectively, after achieving complete resolution of their t...
Medicenna Strengthens Intellectual Property Portfolio with Five Patent...
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation of bizaxofusp TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for oncology and autoimmune diseases, today announced gr...
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and ...
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® at medical conferences and a planned KOL event MDNA11 continues to exhibit compelling deep and durable anti-tumor activity in difficult-to-treat solid tumors with best-in-class potential relative to competing IL-2 programs Results presented at the 2025 AACR showed response rates in the 30-50% ra...
Medicenna Presents Promising Preclinical Data from its First-in-Class ...
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SK to the tumor microenvironment (TME) IL-13Rα2 is overexpressed by some of the most “immunologically cold” tumors with high unmet needs in pancreatic, liver, brain, breast, colon and prostate cancer that annually affect over 2 million patient...
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Tria...
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic cancers with resistance to immune checkpoint inhibitors (ICI) or with historically low responses to ICI Combination of MDNA11 with KEYTRUDA in the dose escalation arm achieved an objective response rate (ORR) of 36% (5 of 14) in all tumor types enrolling in the Phase 2 expansion co...
Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investo...
Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto on May 5-6, 2025. Details on the pres...
Medicenna to Present at Jones Healthcare and Technology Innovation Con...
Medicenna to Present at Jones Healthcare and Technology Innovation Conference TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the Jones Healthcare and Technology Innovation Conference, to be held April 8-9, 2025 in Las Vegas, Nevada. Details on the ...
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at ...
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional anti-PD1-IL2 Superkine, MDNA113, will also be presented TORONTO and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines ta...
Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associat...
Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a 30% (3 of 10) objective response rate (ORR) in the monotherapy dose expansion cohort in checkpoint-resistant patients (as of Dec. 5, 2024) Disease control rate (DCR) of ...
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational ...
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1 trial including one complete response, one partial response and five stable disease (as reported on Dec. 5, 2024) - MDNA11 continued to demonstrate deep and durable single agent activity, with a 30% (3 of 10) objective response rate (ORR) in the monotherapy dose expansion cohort in ...
Medicenna Therapeutics to Participate in Two Healthcare Investor Confe...
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025 TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer, and inflammatory and autoimmune diseases, today announced that its management team will participate in two upcoming investor conferences in February 2025. The company will also host one-on-one meetings with investors during these events. Oppenheimer...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.